Cancer of esophagogastric junction
Showing 1 - 25 of >10,000
Novel Staging Schemes for Siewert Type II Esophagogastric
Completed
- Adenocarcinoma of the Esophagogastric Junction
- esophagogastric junction cancer surgery
-
Fuzhou, Fujian, ChinaFujian Medical University Union Hospital
Nov 1, 2022
Epiphora Due to Insufficient Drainage, Left Side, Epiphora Due to Insufficient Drainage, Right Side Trial in Tianjin
Recruiting
- Epiphora Due to Insufficient Drainage, Left Side
- Epiphora Due to Insufficient Drainage, Right Side
- Esophagogastric Side to Side Anastomosis
- Esophagogastric End to Side Anastomosis
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Apr 2, 2023
Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation Trial in China (Radiotherapy, Platinum based chemo, Paclitaxel
Recruiting
- Esophagus Cancer
- +5 more
- Radiotherapy
- +5 more
-
Anyang, Henan, China
- +4 more
Aug 17, 2022
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer Trial in China
Not yet recruiting
- Adenocarcinoma of the Stomach
- +2 more
- Toripalimab
- +2 more
-
Hangzhou, Zhejiang, China
- +7 more
Feb 7, 2023
Neoadjuvant Chemotherapy and Immunotherapy for HER2(-),pMMR
Recruiting
- Gastric Cancer
- SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Sep 12, 2022
Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)
Active, not recruiting
- Stomach Neoplasms
-
Shanghai, ChinaRenji Hospital
Apr 3, 2023
Carcinoma, Gastrointestinal Diseases, Stomach Cancer Trial (Anlotinib HCl capsule, Penpulimab Injection, XELOX)
Not yet recruiting
- Carcinoma
- +6 more
- Anlotinib hydrochloride capsule
- +2 more
- (no location specified)
Aug 8, 2022
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma Trial in Guangzhou
Recruiting
- Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
- Tucidinostat (chidamide) and PD-1 inhibitor (Toripalimab)
-
Guangzhou, Guangdong, ChinaCancer center of Sun Yat-sen University
Jul 20, 2022
Esophagogastric Junction Adenocarcinoma Trial in Guangzhou (Sintilimab)
Recruiting
- Esophagogastric Junction Adenocarcinoma
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Dec 29, 2021
Gastric Cancer, Esophagogastric Junction Disorder Trial in Beijing (Savolitinib)
Recruiting
- Gastric Cancer
- Esophagogastric Junction Disorder
-
Beijing, Beijing, ChinaBeijing Cancer Hopspital
Aug 30, 2021
CAR T-Cell Therapy Trial in Shenzhen (HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T
Recruiting
- CAR T-Cell Therapy
- HEC-016(0.5×10^6 CAR-T Cells)
- +2 more
-
Shenzhen, Guangdong, ChinaShenzhen Luohu Hospital
Mar 3, 2022
Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer Trial run by the National Cancer Institute (NCI) (Surgery,
Recruiting
- Gastric Adenocarcinoma
- +2 more
- Surgery
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Esophagogastric Tumors, Gastric Cancer, Gastric Tumor Trial in United States (Trastuzumab, Pembrolizumab)
Recruiting
- Esophagogastric Tumors
- +9 more
-
Basking Ridge, New Jersey
- +6 more
Jul 8, 2022
Stomach Tumor, Gastrointestinal Tumors, Digestive System Tumor Trial in Havana (Ocoxin-Viusid®)
Recruiting
- Stomach Neoplasm
- +9 more
- Ocoxin-Viusid®
-
Havana, La Habana, CubaNational Institute of Oncology and Radiobiology (INOR)
Oct 20, 2021
Gastroesophageal Junction Adenocarcinoma Trial in Shijiazhuang (Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent
Completed
- Gastroesophageal Junction Adenocarcinoma
- Oxaliplatin; Capecitabine
- Oxaliplatin; Capecitabine; concurrent radiotherapy
-
Shijiazhuang, Hebei, ChinaDepartment of General Surgery
Feb 4, 2022
Gastric Tumor, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Dresden, Heidelberg (Biopsy)
Active, not recruiting
- Gastric Neoplasm
- +4 more
- Biopsy
-
Dresden, Germany
- +1 more
Feb 22, 2022
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction Trial run by the NCI (Paclitaxel, Capecitabine, BardPort
Recruiting
- Gastric Adenocarcinoma
- +3 more
- Paclitaxel
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Gastric Cancer Trial in Frankfurt am Main (5-Fluorouracil, Leucovorin, Oxaliplatin)
Recruiting
- Gastric Cancer
- 5-Fluorouracil
- +6 more
-
Frankfurt am Main, GermanyKrankenhaus Nordwest
Feb 21, 2022
Esophageal Cancer, Esophagogastric Junction Cancer Trial in Worldwide (Autologous genetically modified ADP-A2M4CD8 cells)
Recruiting
- Esophageal Cancer
- Esophagogastric Junction Cancer
- Autologous genetically modified ADP-A2M4CD8 cells
-
Duarte, California
- +33 more
Aug 23, 2022
Gastric or Esophagogastric Junction Adenocarcinoma Trial (nimotuzumab plus paclitaxel, plus paclitaxel)
Not yet recruiting
- Gastric or Esophagogastric Junction Adenocarcinoma
- nimotuzumab plus paclitaxel
- placebo plus paclitaxel
- (no location specified)
Aug 3, 2023
Esophageal Cancer, Esophagogastric Junction Cancer Trial in Lexington (drug, radiation, procedure)
Not yet recruiting
- Esophageal Cancer
- Esophagogastric Junction Cancer
- Intravenous Tislelizumab
- +3 more
-
Lexington, KentuckyUniversity of Kentucky
Feb 21, 2022
Esophagus Cancer Trial in Loma Linda (Proton radiation)
Recruiting
- Esophagus Cancer
- Proton radiation
-
Loma Linda, CaliforniaLoma Linda University Medical Center
Feb 16, 2022
Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer Trial in Beijing (IM92 CAR-T cells)
Recruiting
- Advanced Solid Tumors
- +3 more
- IM92 CAR-T cells
-
Beijing, Beijing, ChinaChinese PLA GENERAL HOSPITAL
Mar 10, 2022
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma Trial
Not yet recruiting
- Adenocarcinoma of the Stomach
- +2 more
- Toripalimab
- +2 more
-
Hangzhou, Zhejiang, China
- +7 more
Jul 25, 2023
Gastric and Esophagogastric Junction Adenocarcinoma Trial in Zhengzhou (PD-1 Monoclonal Antibody(Sintilimab))
Recruiting
- Gastric and Esophagogastric Junction Adenocarcinoma
- PD-1 Monoclonal Antibody(Sintilimab)
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Aug 23, 2021